Ptc Therapeutics (PTCT) Net Cash Flow Growth (1y) (2013 - 2026)
Ptc Therapeutics (PTCT) Net Cash Flow Growth (1y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,440.76 Bn | 66,440.47 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,880.51 Bn | 1,880.45 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 467.94 Bn | 463.15 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 122.63 Bn | 115.38 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 70.30 Bn | 61.54 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.81 Bn | 62.81 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.59 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn | 53.46% |
| 10 | Ptc Therapeutics | 6.33 Bn | 4.44 Bn | 244.52 Mn | -121.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -121.06% |
| Dec 31, 2025 | 14.41% |
| Sep 30, 2025 | -148.16% |
| Jun 30, 2025 | -536.62% |
| Mar 31, 2025 | 1,693.25% |
| Dec 31, 2024 | -37.95% |
| Sep 30, 2024 | -236.88% |
| Jun 30, 2024 | 662.05% |
| Mar 31, 2024 | 19.75% |
| Dec 31, 2023 | 151.35% |
| Sep 30, 2023 | 2.02% |
| Jun 30, 2023 | -193.00% |
| Mar 31, 2023 | -15.20% |
| Dec 31, 2022 | 4,371.86% |
| Sep 30, 2022 | -352.24% |
| Jun 30, 2022 | -27.84% |
| Mar 31, 2022 | 21.97% |
| Dec 31, 2021 | 101.63% |
| Sep 30, 2021 | -94.01% |
| Jun 30, 2021 | -15.73% |